Published in Gene Therapy Weekly, August 4th, 1997
The findings provide the basis for vast improvement of the current system for selecting influenza vaccine antigens, suggest a research team from the University of California, Irvine, and the U.S. Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
"It is possible ... that we now have most of the [amino-acid] residues upon which the virus depends for immune avoidance," wrote UCI researcher Walter M. Fitch and colleagues in the Proceedings of the National Academy of Sciences ("Long Term Trends in the Evolution of H(3) HA1 Human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.